All Articles

A beautiful case study exemplifying the power of navigation when executed in collaboration with the patient, caregivers, and care team.

Active surveillance is gaining ground as a strategy for managing small renal masses. According to intermediate follow-up of the prospective Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) registry, active surveillance appears as safe as primary intervention in selected patients. In general, active surveillance is a good option for elderly patients with comorbidities and renal masses <4 cm.

Atezolizumab plus bevacizumab showed encouraging responses as a first-line approach to treatment of metastatic renal cell carcinoma (mRCC) in a phase 2 trial.

Despite consultations with oncologists about the goal of treatment, more than one-third of men with incurable prostate cancer believed that a cure was possible with the treatments they were about to receive.

Starting at a low dose of sorafenib and titrating up to the full dose of 800 mg, rather than starting at the full dose, does not adversely affect outcomes and improves tolerability and reduces costs in the treatment of patients with hepatocellular carcinoma (HCC).

Adding vemurafenib to cetuximab and irinotecan prolonged progression-free survival (PFS) and improved the disease control rate in patients with BRAF V600E mutation–positive colorectal cancer (CRC).

The multitargeted tyrosine kinase inhibitor (TKI) cabozantinib demonstrated encouraging activity in patients with advanced neuroendocrine tumors (NETs), including patients previously treated with sunitinib or everolimus, a preliminary clinical study showed.

Constant exposure to patient distress and trauma can take a toll on oncology workers, and it often leads to a phenomenon called secondary traumatic stress, or “compassion fatigue,” according to Charles Figley, PhD, Paul Henry Kurzweg Chair in Disaster Mental Health and Director of the Traumatology Institute at Tulane University in New Orleans, LA.

Innovation takes time, especially when it comes to cancer research. Unfortunately, delays in the adoption of novel oncology treatments can have a significant effect on patient health.

The FDA’s new personalized medicine approvals and expanded indications reflect the extraordinary pace of scientific innovation in the field.